The total number of records retrieved from this search are 54. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_489	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result98% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_493	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result85% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_497	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result96% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_501	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result78% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_505	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result60% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_509	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_513	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result88% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_517	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_521	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_525	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result32% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_529	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result66% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_533	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result58% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_537	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_541	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_545	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result23% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_549	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration1 MOI	In-vitro result16% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_553	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration5 MOI	In-vitro result16% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_557	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration10 MOI	In-vitro result16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_561	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration50 MOI	In-vitro result16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_565	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell line143-B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentration100 MOI	In-vitro result12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_2867	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell line143-B	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2868	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell line143-B	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2869	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell line143-B	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2870	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell line143-B	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_3207	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3208	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3209	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3210	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3211	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3212	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3213	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3214	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3215	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3216	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3217	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3218	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3219	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3220	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result73% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3221	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3222	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result55% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3223	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3224	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3225	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result70% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3226	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3227	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3228	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3229	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3230	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3231	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3232	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3233	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3234	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3235	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3236	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891